Seres Therapeutics, Inc. (MCRB)
Nasdaq · Healthcare · Biotechnology
$2.85−3.06%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $28.6M
- 52-week range
- $2.81 – $29.98
- 52-week change
- −85.37%
- EPS (trailing)
- −$2.42
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $789K
- Net income
- $5.7M
- Operating margin
- −11910.1%
- Diluted EPS
- $0.64
- Free cash flow
- $870K
From the company’s annual report on SEC EDGAR.
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Headquarters: Cambridge, United States · 66 employees · serestherapeutics.com